Sarepta Therapeutics (NASDAQ:SRPT) Trading 7.2% Higher - Should You Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares were up 7.2% during trading on Tuesday . The stock traded as high as $18.25 and last traded at $18.57. Approximately 599,791 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 2,196,379 shares. The stock had previously closed at $17.32.

Analyst Upgrades and Downgrades

Several analysts recently commented on SRPT shares. Deutsche Bank Aktiengesellschaft lowered their target price on Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating on the stock in a research report on Tuesday, June 17th. Guggenheim decreased their price target on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Piper Sandler lowered Sarepta Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $70.00 to $36.00 in a research note on Monday, June 16th. Wells Fargo & Company decreased their price target on Sarepta Therapeutics from $100.00 to $75.00 and set an "overweight" rating for the company in a research note on Tuesday, June 17th. Finally, Scotiabank raised Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price target for the company in a research note on Friday, June 6th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics has an average rating of "Hold" and a consensus target price of $60.88.

Sarepta Therapeutics Trading Up 9.5%

The company has a fifty day simple moving average of $34.46 and a two-hundred day simple moving average of $74.09. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The company has a market capitalization of $1.86 billion, a P/E ratio of -7.05 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same quarter last year, the business earned $0.73 earnings per share. Sarepta Therapeutics's quarterly revenue was up 80.2% on a year-over-year basis. On average, analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors have recently made changes to their positions in SRPT. Smartleaf Asset Management LLC increased its stake in shares of Sarepta Therapeutics by 95.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 216 shares during the period. Jones Financial Companies Lllp grew its position in Sarepta Therapeutics by 274.5% during the fourth quarter. Jones Financial Companies Lllp now owns 528 shares of the biotechnology company's stock worth $64,000 after buying an additional 387 shares in the last quarter. Steward Partners Investment Advisory LLC grew its position in Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after buying an additional 194 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Sarepta Therapeutics by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after buying an additional 12,000 shares in the last quarter. Finally, Victory Capital Management Inc. grew its position in Sarepta Therapeutics by 34.0% during the fourth quarter. Victory Capital Management Inc. now owns 88,808 shares of the biotechnology company's stock worth $10,798,000 after buying an additional 22,529 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.